Naschitz, Jochanan E, Yeshurun, Daniel, Rosner, Itzhak · Medical hypotheses · 2004 · DOI
This study looked at whether people with ME/CFS have problems with their autonomic nervous system—the part that automatically controls heart rate and blood pressure. Researchers found a distinctive pattern of dysautonomia (autonomic dysfunction) in ME/CFS patients that differs from other conditions, and they developed two scoring systems to help identify it. A small pilot study suggested that treating this dysautonomia with a medication called midodrine improved both the autonomic problems and fatigue symptoms.
This research is important because it proposes objective biomarkers (HIS and FRAS scores) that could help diagnose ME/CFS, moving beyond purely subjective clinical criteria. If dysautonomia is indeed central to ME/CFS pathophysiology, it suggests autonomic-targeted treatments like midodrine could offer therapeutic benefits for many patients.
This study does not prove that dysautonomia causes ME/CFS or that treating dysautonomia will cure the illness in all patients. The pilot midodrine data are preliminary and do not establish efficacy across the broader ME/CFS population. Findings are correlational and mechanistic—they suggest a relationship but do not rule out dysautonomia being a consequence rather than a primary cause of ME/CFS.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →